Development of Cell-Penetrating Asymmetric Interfering RNA Targeting Connective Tissue Growth Factor

Area of Science:

• Biochemistry
• Molecular Biology
• Dermatology

Background:

• Connective tissue growth factor (CTGF) is a key mediator in tissue remodeling and fibrosis.
• CTGF plays a pivotal role in the progression of fibrotic disorders like hypertrophic scars and keloids.
• CTGF represents a promising therapeutic target for antifibrotic treatments.

Purpose of the Study:

• To develop an RNA molecule capable of inhibiting CTGF expression via RNA interference.
• To create a cell-penetrating interfering RNA (cp-asiRNA) that functions without delivery vehicles.
• To evaluate the efficacy of cp-asiCTGF in vitro and in vivo for potential antifibrotic therapy.

Main Methods:

• Development of an asymmetric interfering RNA (asiRNA) with chemical modifications to create cell-penetrating asiRNA (cp-asiRNA).
• In vitro and in vivo assessment of cp-asiRNA targeting CTGF (cp-asiCTGF) for gene silencing activity.
• Administration of cp-asiCTGF in a rat skin excision wound model to evaluate its effect on CTGF and collagen induction.

Main Results:

• The developed cp-asiRNA efficiently inhibited CTGF expression through RNA interference in both in vitro and in vivo settings.
• cp-asiCTGF demonstrated successful cellular uptake and gene silencing without the need for external delivery systems.
• In vivo administration of cp-asiCTGF significantly reduced CTGF and collagen levels during wound healing in rats.

Conclusions:

• The cell-penetrating asiRNA targeting CTGF (cp-asiCTGF) is an effective inhibitor of CTGF expression.
• cp-asiCTGF holds potential as a therapeutic agent for fibrotic conditions.
• This technology could be developed into novel antiscar drugs and other antifibrotic therapeutics.